These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 33416163)
1. Zoledronic acid re‑sensitises gefitinib‑resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelial‑mesenchymal transition. Yang X; Gao Y; Liu Q; Wan L; Liu H; Bian W; Du Y; Huang C Oncol Rep; 2021 Feb; 45(2):459-468. PubMed ID: 33416163 [TBL] [Abstract][Full Text] [Related]
2. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition. Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374 [TBL] [Abstract][Full Text] [Related]
3. Triptolide inhibits epithelial‑mesenchymal transition and induces apoptosis in gefitinib‑resistant lung cancer cells. Li F; Cui H; Jin X; Gong X; Wang W; Wang J Oncol Rep; 2020 May; 43(5):1569-1579. PubMed ID: 32323848 [TBL] [Abstract][Full Text] [Related]
4. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Cao W; Liu Y; Zhang R; Zhang B; Wang T; Zhu X; Mei L; Chen H; Zhang H; Ming P; Huang L Sci Rep; 2015 Jul; 5():8477. PubMed ID: 26166037 [TBL] [Abstract][Full Text] [Related]
5. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001 [TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations. Feng C; Liu X; Li X; Guo F; Huang C; Qin Q; Wang Y Oncol Rep; 2016 Jun; 35(6):3460-70. PubMed ID: 27109760 [TBL] [Abstract][Full Text] [Related]
7. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3. Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264 [TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066 [TBL] [Abstract][Full Text] [Related]
9. Mechanistic insights into Yifei Sanjie pill's regulation of EMT to enhance gefitinib treatment effect in NSCLC by in silico analysis and experimental validation. Zhou R; Qin B; Zhuang Z; Li J; Shi Y; Gao T; Wu D; Yuan Y; Tang Y; Lin L J Ethnopharmacol; 2024 Nov; 334():118343. PubMed ID: 38750985 [TBL] [Abstract][Full Text] [Related]
10. Silencing of Zhang P; Li Z; Yang G Int J Mol Med; 2021 Dec; 48(6):. PubMed ID: 34713300 [TBL] [Abstract][Full Text] [Related]
11. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507 [TBL] [Abstract][Full Text] [Related]
12. Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo. Zhu H; Cheng H; Ren Y; Liu ZG; Zhang YF; De Luo B Mol Biol Rep; 2012 Apr; 39(4):4971-9. PubMed ID: 22160570 [TBL] [Abstract][Full Text] [Related]
13. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220 [TBL] [Abstract][Full Text] [Related]
14. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. Li F; Zhu T; Cao B; Wang J; Liang L Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888 [TBL] [Abstract][Full Text] [Related]
15. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway. Xiao Z; Li M; Zhang X; Rong X; Xu H Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765 [TBL] [Abstract][Full Text] [Related]
16. The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer. Du W; Sun L; Liu T; Zhu J; Zeng Y; Zhang Y; Wang X; Liu Z; Huang JA Oncol Rep; 2020 Jul; 44(1):185-195. PubMed ID: 32319651 [TBL] [Abstract][Full Text] [Related]
17. Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis. Yu B; Zheng L; Tang H; Wang W; Lin Y Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396444 [TBL] [Abstract][Full Text] [Related]
18. Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth. Xu L; Meng X; Xu N; Fu W; Tan H; Zhang L; Zhou Q; Qian J; Tu S; Li X; Lao Y; Xu H Cell Death Dis; 2018 Feb; 9(3):262. PubMed ID: 29449529 [TBL] [Abstract][Full Text] [Related]
19. Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer. Sudo M; Chin TM; Mori S; Doan NB; Said JW; Akashi M; Koeffler HP Cancer Chemother Pharmacol; 2013 May; 71(5):1325-34. PubMed ID: 23515752 [TBL] [Abstract][Full Text] [Related]
20. Omega-3 Fatty Acid-Enriched Fish Oil and Selenium Combination Modulates Endoplasmic Reticulum Stress Response Elements and Reverses Acquired Gefitinib Resistance in HCC827 Lung Adenocarcinoma Cells. Liao CH; Tzeng YT; Lai GM; Chang CL; Hu MH; Tsai WL; Liu YR; Hsia S; Chuang SE; Chiou TJ; Wang LM; Whang-Peng J; Yao CJ Mar Drugs; 2020 Jul; 18(8):. PubMed ID: 32751169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]